MiNK Q1 cash $9.5M, net loss $2.7M; initiates randomized Phase 2 for agenT-797 in ARDS

MiNK Therapeutics, Inc.

Cash $9.5M at Mar 31 (down from $13.4M at Dec 31); repaid $5.2M Agenus convertible note.
Net loss $2.7M ($0.57/sh) vs $2.8M ($0.70/sh) year ago; raised $3.0M via ATM in Q1.
Initiated randomized Phase 2 trial of agenT-797 in severe acute lung injury/ARDS; data expected H2 2026.
Non-dilutive C-Further collaboration provides up to $1.1M for PRAME-targeted iNKT therapy in pediatric cancers.
Upcoming ATS presentation May 20 on agenT-797 for coccidioides infection; NIH-funded GvHD program ongoing.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

MiNK Therapeutics, Inc. reported financial results for the first quarter ending March 31, 2026.

Period: the first quarter ending March 31, 2026
Result: reported results

Exact text from the filing

On May 15, 2026, MiNK Therapeutics, Inc. announced its financial results for the quarter ended March 31, 2026.

View on SEC.gov

Browse all earnings releases →

MiNK Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-225369

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.